Praveenkumar Murugavelu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Praveenkumar Murugavelu has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
Alona Kuzmina
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
1 shared publication- Ferdinand Heyn
Department of Internal Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
1 shared publication - Heli Glebko
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
1 shared publication Ina Ambiel
Department of Infectious Diseases, Integrative Virology, CIID, Heidelberg University, Medical Faculty Heidelberg, Heidelberg, Germany
1 shared publication- Jagrity Rani
The Shraga Segal Department of Microbiology, Immunology and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel
1 shared publication Liron Levin
Bioinformatics Core Facility, llse Katz Institute for Nanoscale Science and Technology, Ben-Gurion University of the Negev, Beer-Sheva, Israel
1 shared publication
Latest Publications
- Open Access
- 6 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (11) , 4558-4584
Inhibition of CDK12/CDK13-CYCLIN K rewires P-TEFb signaling to reverse HIV-1 latency and modulate cellular gene expression
Persistent HIV-1 latency in long-lived CD4⁺ T-cell reservoirs remains a major obstacle towards viral eradication. Current antiretroviral therapy (cART) exhibits limited clinical efficacy, highlighting the need for new therapeutic interventions. Here, we identify the CDK12/CDK13-Cyclin K (CCNK) complex as a regulator of HIV-1 latency. Pharmacological inhibition of CDK12/CDK13-CCNK with the SR-4835 inhibitor robustly reversed HIV-1 latency in the absence of additional stimuli, both in T cell models and in primary CD4⁺ T cells from people living with HIV-1 receiving cART. Targeting of CDK12/CDK13-CCNK with SR-4835 further synergized HIV-1 latency reversal and enhanced viral reactivation when co-treated with established Latency Reversal Agents. Mechanistically, CDK12/CDK13-CCNK inhibition promoted the release of P-TEFb (CDK9/CYCLIN T) from its inhibitory 7SK snRNP complex, resulting in increased recruitment of RNA polymerase II, CDK9 activation, and remodeled chromatin that overall drove productive HIV-1 transcription. Beyond HIV-1 reactivation, our findings reveal a previously unrecognized compensatory interplay between transcriptional kinases that activate gene expression, thereby rewiring cellular transcriptional programs. Together, this study identifies CDK12/CDK13-CCNK complex as a therapeutic target for HIV-1 latency reversal and provides a mechanistic rationale for improving strategies aimed at achieving an HIV cure.
- 6 October 2026
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 18 (11) , 4558-4584
Open AccessInhibition of CDK12/CDK13-CYCLIN K rewires P-TEFb signaling to reverse HIV-1 latency and modulate cellular gene expression
Persistent HIV-1 latency in long-lived CD4⁺ T-cell reservoirs remains a major obstacle towards viral eradication. Current antiretroviral therapy (cART) exhibits limited clinical efficacy, highlighting the need for new therapeutic interventions. Here, we identify the CDK12/CDK13-Cyclin K (CCNK) complex as a regulator of HIV-1 latency. Pharmacological inhibition of CDK12/CDK13-CCNK with the SR-4835 inhibitor robustly reversed HIV-1 latency in the absence of additional stimuli, both in T cell models and in primary CD4⁺ T cells from people living with HIV-1 receiving cART. Targeting of CDK12/CDK13-CCNK with SR-4835 further synergized HIV-1 latency reversal and enhanced viral reactivation when co-treated with established Latency Reversal Agents. Mechanistically, CDK12/CDK13-CCNK inhibition promoted the release of P-TEFb (CDK9/CYCLIN T) from its inhibitory 7SK snRNP complex, resulting in increased recruitment of RNA polymerase II, CDK9 activation, and remodeled chromatin that overall drove productive HIV-1 transcription. Beyond HIV-1 reactivation, our findings reveal a previously unrecognized compensatory interplay between transcriptional kinases that activate gene expression, thereby rewiring cellular transcriptional programs. Together, this study identifies CDK12/CDK13-CCNK complex as a therapeutic target for HIV-1 latency reversal and provides a mechanistic rationale for improving strategies aimed at achieving an HIV cure.
- 25 August 2026
- Published by EMBL-EBI
Targeting CDK12/CDK13-CYCLIN K induces HIV-1-specific and global gene activation mediated by P-TEFb
BioStudies – one package for all the data supporting a study
- 25 August 2026
- Published by EMBL-EBI
Targeting CDK12/CDK13-CYCLIN K induces HIV-1-specific and global gene activation mediated by P-TEFb
BioStudies – one package for all the data supporting a study